0.0000 (0.0000%)
  • Bid / Lots
    1.3100/ 3
  • Ask / Lots
    1.3300/ 5
  • Open / Previous Close
    1.3100 / 1.3100
  • Day Range
    Low 1.2900
    High 1.3300
  • 52 Week Range
    Low 0.9700
    High 2.6700
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.33
09:32 ET20511.32
09:35 ET23271.29
09:42 ET8001.3001
09:48 ET2001.315
09:51 ET2001.315
09:55 ET1001.33
10:08 ET1001.3264
10:11 ET2461.33
10:15 ET5001.3299
10:27 ET1001.33
10:38 ET6601.32
10:47 ET4001.31
10:54 ET12001.3101
10:56 ET9501.3
11:03 ET2001.305
11:21 ET3001.3
11:23 ET15501.3099
11:38 ET10001.3099
11:39 ET5001.3081
11:54 ET1001.3119
12:06 ET4001.31
12:08 ET2121.32
12:14 ET1001.32
12:19 ET5001.32
12:37 ET1001.32
12:48 ET1001.33
12:50 ET5001.3299
12:51 ET3001.32
12:55 ET1331.31
01:06 ET47001.31
01:20 ET1201.3
01:22 ET2501.3099
01:31 ET1001.31
02:05 ET10001.3
02:09 ET5001.309
02:20 ET11001.305
02:25 ET6001.305
02:27 ET3001.305
02:30 ET24801.3
02:34 ET4501.31
02:41 ET1001.31
02:48 ET6001.32
02:54 ET1501.3176
03:01 ET1001.3175
03:08 ET3501.3007
03:30 ET1001.31
03:39 ET41361.3199
03:46 ET1001.31
03:51 ET7951.32
03:55 ET1001.32
04:00 ET2001.31
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGNPX
Genprex Inc
United StatesRPHM
Reneo Pharmaceuticals Inc
United StatesBCEL
Atreca Inc
United StatesAPTO
Aptose Biosciences Inc
United StatesGALT
Galectin Therapeutics Inc
United StatesSPRB
Spruce Biosciences Inc
As of 2023-01-27

Company Information

Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogen therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a multifunctional gene that helps in cancer suppression and normal cell regulation. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Contact Information

Suite 3.322 1601 Trinity Street, Bldg. BAUSTIN, TX, United States 78712


Chairman of the Board, President, Co-Founder, Company Secretary
J. Rodney Varner
Chief Financial Officer
Ryan Confer
Executive Vice President, General Counsel, Chief Strategy Officer
Catherine Vaczy
Chief Manufacturing and Technology Officer
Hemant Kumar
Chief Medical Officer
Mark Berger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.